3-Amino-2-[[(2,6-dioxopiperidin-3-yl)amino]methyl]benzaldehyde

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Amino-2-[[(2,6-dioxopiperidin-3-yl)amino]methyl]benzaldehyde
• 英文别名: 3-amino-2-[[(2,6-dioxopiperidin-3-yl)amino]methyl]benzaldehyde
• 化学式: C₁₃H₁₅N₃O₃
• 分子量: 261.28
• InChiKey: MAURAPZOACOXCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] TARGETED THERAPEUTICS<br/>[FR] THÉRAPEUTIQUE CIBLÉE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015038649A1

  公开（公告）日：2015-03-19

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了包括与将效应子导向至感兴趣的生物靶点的结合基团共轭的药理化合物。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应子。例如，在针对治疗癌症的某些实施方式中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒性药剂作为效应子。
• [EN] COMPOUNDS AND METHODS OF TREATING CANCERS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE CANCERS
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2022073469A1

  公开（公告）日：2022-04-14

  This disclosure relates to GSPT1 degrader compounds (e.g. small molecule compounds), compositions comprising one or more of the compounds, and to methods of use the compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such compounds.

  本公开涉及GSPT1降解剂化合物（例如小分子化合物），包含一种或多种该化合物的组合物，以及使用该化合物治疗特定疾病的方法，适用于需要该治疗的个体。本公开还涉及识别这种化合物的方法。
• ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Kangpu Biopharmaceuticals, Ltd.

  公开号：EP3214081A1

  公开（公告）日：2017-09-06

  Provided are an isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof. The isoindoline derivative and the pharmaceutical composition thereof can regulate the production or activity of immunological cytokines, thus effectively treating cancer and inflammatory disease.

  本文提供了一种异吲哚啉衍生物、中间体、制备方法、药物组合物及其用途。异吲哚啉衍生物及其药物组合物可以调节免疫细胞因子的产生或活性，从而有效治疗癌症和炎症性疾病。
• [EN] ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] DÉRIVÉ D'ISOINDOLINE, SON INTERMÉDIAIRE, SON PROCÉDÉ DE PRÉPARATION, SA COMPOSITION PHARMACEUTIQUE ET SON UTILISATION<br/>[ZH] 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
  申请人：KANGPU BIOPHARMACEUTICALS INC

  公开号：WO2016065980A1

  公开（公告）日：2016-05-06

  提供一种异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用。该异吲哚啉衍生物及其药物组合物能够调节免疫细胞因子的产生或活性，从而有效的治疗癌症和炎症性疾病。
• [EN] TARGETED THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLÉS
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2013158644A2

  公开（公告）日：2013-10-24

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.